Assertio Holdings Inc. Reports Q1 2025 Net Product Sales of $26 Million; Adjusted EBITDA Falls to $0.2 Million from $7.4 Million Previous Year

Reuters
05-13
Assertio Holdings Inc. Reports Q1 2025 Net Product Sales of $26 Million; Adjusted EBITDA Falls to $0.2 Million from $7.4 Million Previous Year

Assertio Holdings Inc. announced its financial results for the first quarter of 2025, reporting total net product sales of $26.0 million, aligning with the company's 2025 outlook. This represents a decrease from the $31.9 million recorded in the same quarter of the previous year. The company reported a net loss of $13.5 million, compared to a net loss of $4.5 million in the prior year quarter. Adjusted EBITDA was significantly lower at $0.2 million, down from $7.4 million in the first quarter of the previous year. This decrease was primarily attributed to lower net product sales and increased cost of sales due to higher Rolvedon volumes. Rolvedon net product sales were $13.1 million, a decline from $14.5 million in the previous year, driven by lower pricing despite higher volume. As part of its long-term business strategy, Assertio aims to create sustainable near-term growth and increased long-term value, focusing on its commercial assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001808665-25-000011), on May 12, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10